Home Antibody All anti-F13A1 antibodies
Anti-F13A1 TRUEMAB Antibody Clone OTI3G12
TrueMAB Antibodies - Made against Authentic Protein Antigens
Write Review & Get Rewarded
Write a review and get rewarded!
Review this antibody and earn an OriGene coupon or Amazon giftcard
Follow these easy steps to reward yourself:
- Sign in to your account, or register for a new account;
- Write a review;
- Receive a coupon or giftcard once your review is accepted.
Click the button to start writing a review
Also for F13A1 (NM_000129)
|Full length human recombinant protein of human F13A1 (NP_000120) produced in HEK293T cell.|
||WB 1:2000, IHC 1:150,
|PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.|
|Purified from mouse ascites fluids by affinity chromatography
|Homo sapiens coagulation factor XIII A chain (F13A1)|
Entrez Gene 2162 Human
|This gene encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion. [provided by RefSeq, Jul 2008].|
|Secreted ProteinDruggable Genome Complement and coagulation cascades|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY F13A1 (RC206464, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-F13A1.
Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-F13A1 monoclonal antibody (HepG2: human; HeLa: human; SVT2: mouse; A549: human; COS7: monkey; Jurkat: human; MDCK: canine; PC12: rat; MCF7: human).
Immunohistochemical staining of paraffin-embedded Carcinoma of Human bladder tissue using anti-F13A1 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA800370)
Immunohistochemical staining of paraffin-embedded Human lymph node tissue within the normal limits using anti-F13A1 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA800370)
Immunohistochemical staining of paraffin-embedded Human lymphoma tissue using anti-F13A1 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA800370)